In The Lancet Regional Health – Europe: important real-world insights into the prevalence and prognosis of pts with early ER+/HER2- breast cancer who may be eligible for adjuvant CDK4/6 inhibitors: #monarchE and #NATALEE compared to #PANTHER trial #GBG53
www.sciencedirect.com/science/arti...